Comunque, se parte effettivamente una nuova fase di debito, potrebbero esserci delle discrete opportunità anche sull'HY europeo... ad es, per l'acquisto della divisione pharma di Solvay pareva avesse la meglio la svizzera Nycomed con un LBO per il quale era preventivata un'emissione HY nel pharma da 2 mld euro... con un leverage neanche particolarmente elevato ed in un comparto piuttosto conservativo... poi purtroppo la cosa è sfumata per il rilancio al rialzo di Abbot Lab, ma queste sono situazioni da tenere d'occhio, per il futuro...
Comparto difensivo, leverage non eccessivo, premio al rischio per le nuove emissioni HY interessante, specie nel contesto europeo...
Recentemente c'è stato un caso interessante di questo tipo, ma solo bond in USD...
Ma in banca, quando gli dici del tuo profilo di rischio, come commentano ?
L'emittente in questione é Warner Chilcott... il solo bond acquistabile ad oggi per il retail è in USD... il bond non è una nuova emissione, il caso interessante riguarda l'andamento del processo di deleverage, ma come rating è basso...
E' atteso un bond di nuova emissione, sempre in USD...
E invece niente: hanno preferito attingere ulteriormente al credito bancario secured, e le banche glielo hanno erogato volentieri, nonostante il rating ampiamente speculativo...
Moody's lowers Warner Chilcott's bank rating to B1; affirms CFR
Rating action reflects revised capital structure with sr. unsecured notes replaced with sr. secured bank debt.
New York, October 09, 2009 -- Moody's Investors Service lowered the recently assigned rating on the recently rated senior secured credit facilities of Warner Chilcott Corporation, Warner Chilcott Company, LLC and WC Luxco S.à r.l. (subsidiaries of Warner Chilcott plc, collectively referred to as "Warner Chilcott") to B1 from Ba3. At the same time, Moody's affirmed Warner Chilcott's B1 Corporate Family Rating, B1 Probability of Default Rating, B3 senior subordinated rating and SGL-1 speculative grade liquidity rating. The rating outlook remains stable.
This rating action reflects a change in Warner Chilcott's proposed capital structure rated by Moody's on September 28, 2009. Following the change, $450 million of senior unsecured notes will be replaced with incremental senior secured bank debt of $450 million.
The change in Warner Chilcott's capital structure results in a higher proportion of senior secured debt and a lower portion of senior unsecured debt. Based on application of Moody's Loss Given Default Rating Methodology, the senior secured debt is now rated the same as Warner Chilcott's B1 Corporate Family Rating. Moody's believes it is possible that rapid reduction of senior secured debt could result in an upgrade of the rating on the credit facilities. However, the pace and timing of debt reduction is not yet certain enough to maintain the Ba3 rating on the senior secured credit facilities.
Ratings lowered:
Warner Chilcott Corporation, Warner Chilcott Company, LLC and WC Luxco S.à r.l. (Borrowers)
Senior secured Term Loan A of $1.0 billion due 2014 to B1 [LGD4, 44%] from Ba3 [LGD3, 37%]
Ba3 [LGD3, 37%]
Senior secured Term Loan B of $1.95 billion due 2015 to B1 [LGD4, 44%] from Ba3 [LGD3, 37%], with commitment size increased to $1.95 billion from $1.5 billion
Senior secured revolving credit facility of $250 million due 2014 to B1 [LGD4, 44%] from Ba3 [LGD3, 37%]
Rating withdrawn:
Warner Chilcott Company, LLC and Warner Chilcott Finance LLC (Co-Issuers)
B3 [LGD5, 85%] senior unsecured notes of $450 million due 2017
Rating affirmed with LGD point estimate revisions:
Warner Chilcott Corporation
B3 [LGD6, 93%] senior subordinated notes of $380 million due 2015
Moody's last rating action on Warner Chilcott was assignment of ratings to proposed senior secured credit facilities and senior unsecured notes on September 28, 2009.
The principal methodology used in rating Warner Chilcott was Moody's Global Pharmaceutical Rating Methodology, published in November 2004 and available on
OpenDNS in the Rating Methodologies sub-directory under the Research & Ratings tab. Other methodologies and factors that may have been considered in the process of rating this issuer can also be found in the Rating Methodologies sub-directory on Moody's website.
Headquartered in Ardee, Ireland, Warner Chilcott plc (NASDAQ: WCRX) is a specialty pharmaceutical company currently focused on the women's healthcare and dermatology segments of the U.S. pharmaceuticals market. For the first six months of 2009, the company reported total revenue of approximately $497 million.